Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cytek Biosciences, Inc. (CTKB : NSDQ)

• Company Description    Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif. Number of Employees: 648

• Price / Volume Information    Yesterday's Closing Price: $3.94 Daily Weekly Monthly 20 Day Moving Average: 871,849 shares Shares Outstanding: 127.22 (millions) Market Capitalization: $501.26 (millions) Beta: 1.36 52 Week High: $7.63 52 Week Low: $2.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.43% -5.13% 12 Week 28.34% 16.58% Year To Date -39.29% -43.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47215 Lakeview Blvd. - Fremont,CA 94538 USA ph: 877-922-9835 fax: - investors@cytekbio.com https://cytekbio.com

• General Corporate Information    Officers Wenbin Jiang - President; Chief Executive Officer and Director William McCombe - Chief Financial Officer Ming Yan - Chief Technology Officer and Director Jack Ball - Director Don Hardison - Director Peer Information Cytek Biosciences, Inc. (CORR.) Cytek Biosciences, Inc. (RSPI) Cytek Biosciences, Inc. (CGXP) Cytek Biosciences, Inc. (BGEN) Cytek Biosciences, Inc. (GTBP) Cytek Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23285D109 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 127.22 Most Recent Split Date: (:1) Beta: 1.36 Market Capitalization: $501.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: 113.54 Price / Sales: 2.56 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 55.56% Sales Growth vs. Year Ago Period: -2.18% vs. Previous Quarter: 10.00% ROE 06/30/25 - -1.66 03/31/25 - -2.90 12/31/24 - -1.54 ROA 06/30/25 - -1.30 03/31/25 - -2.30 12/31/24 - -1.22 Current Ratio 06/30/25 - 5.22 03/31/25 - 5.62 12/31/24 - 5.86 Quick Ratio 06/30/25 - 4.55 03/31/25 - 4.95 12/31/24 - 5.21 Operating Margin 06/30/25 - -3.27 03/31/25 - -5.71 12/31/24 - -3.00 Net Margin 06/30/25 - -3.27 03/31/25 - -5.71 12/31/24 - -3.00 Pre-Tax Margin 06/30/25 - -3.86 03/31/25 - -4.05 12/31/24 - -2.84 Book Value 06/30/25 - 2.98 03/31/25 - 2.98 12/31/24 - 3.07 Inventory Turnover 06/30/25 - 1.93 03/31/25 - 1.91 12/31/24 - 1.83 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.21 03/31/25 - 0.24 12/31/24 - 0.26

Powered by Zacks Investment Research ©